EU/3/06/349

Table of contents

About

On 16 February 2006, orphan designation (EU/3/06/349) was granted by the European Commission to Vectura Group plc, United Kingdom, for apomorphine hydrochloride (inhalation use) for the treatment of off-periods in Parkinson's disease not responding to oral treatment.

The sponsorship was transferred to Vectura Ireland Limited, Ireland in March 2019.

Key facts

Active substance
Apomorphine hydrochloride (inhalation use)
Disease / condition
Treatment of off-periods in Parkinson's disease not responding to oral treatment
Date of first decision
16/02/2006
Outcome
Positive
EU designation number
EU/3/06/349

Sponsor's contact details

Vectura Ireland Limited
The Brickhouse
Block 1, Clanwilliam Court
Lower Mount Street
Dublin 2, D02 CF97
Ireland
Tel. + 353 1541 4798
E-mail: regulatory@vectura.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating